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Background: Despite evidence-based national guidelines for ADHD in the
United Kingdom (UK), ADHD is under-identified, under-diagnosed, and under-treated.
Many seeking help for ADHD face prejudice, long waiting lists, and patchy or unavailable
services, and are turning to service-user support groups and/or private healthcare
for help.
Methods: A group of UK experts representing clinical and healthcare providers
from public and private healthcare, academia, ADHD patient groups, educational,
and occupational specialists, met to discuss shortfalls in ADHD service provision in
the UK. Discussions explored causes of under-diagnosis, examined biases operating
across referral, diagnosis and treatment, together with recommendations for resolving
these matters.
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Results: Cultural and structural barriers operate at all levels of the healthcare system,
resulting in a de-prioritization of ADHD. Services for ADHD are insufficient in many
regions, and problems with service provision have intensified as a result of the response
to the COVID-19 pandemic. Research has established a range of adverse outcomes of
untreated ADHD, and associated long-term personal, social, health and economic costs
are high. The consensus group called for training of professionals who come into contact
with people with ADHD, increased funding, commissioning and monitoring to improve
service provision, and streamlined communication between health services to support
better outcomes for people with ADHD.
Conclusions: Evidence-based national clinical guidelines for ADHD are not being met.
People with ADHD should have access to healthcare free from discrimination, and in
line with their legal rights. UK Governments and clinical and regulatory bodies must act
urgently on this important public health issue.
Keywords: ADHD, service provision, healthcare commissioning, assessment, treatment
BACKGROUND
Attention-deficit/hyperactivity disorder (ADHD) is a common
neurodevelopmental disorder characterized by persistent and
impairing inattention and/or hyperactivity-impulsivity (1, 2).
ADHD usually first presents in childhood, and persists into
adulthood in a sizeable proportion of cases (3, 4).
ADHD is common. Worldwide prevalence, estimated by
standardized procedures in representative samples of the
community, falls between 5 and 7% in children and adolescents
(5, 6), and 2–4% in adults (7–9). Diagnostic and impairment
criteria and source of information contribute to heterogeneity
of estimates (6), and evidence suggests that using the same
diagnostic criteria estimated prevalence rates vary significantly
across different countries with rates being higher in high and
high middle income countries (9). Research indicates significant
genetic influences, environmental risk factors, and differences in
pattern of brain correlates in affected individuals as shown in
neuroimaging studies [reviewed in (10)].
ADHD is associated with a range of adverse outcomes.
People with ADHD are more prone to accidents and injuries,
and have a higher mortality rate compared to the rest of
the population (11, 12). They are more likely to be involved
in delinquency, criminal behavior and substance use (13, 14),
experience early or unplanned pregnancy (15), and experience
challenges in education and at work (16). Associated problems
and comorbidities are common, frequently arise in childhood
Abbreviations: ACAS, advisory, conciliation and arbitration service; ADHD,
attention-deficit/hyperactivity disorder; AMHS, adult mental health services;
ASD, autism spectrum disorders; CAMHS, child and adolescent mental health
services; CBT, cognitive behavioral therapy; CCH, community child health; CCG,
clinical commissioning group; DSM, diagnostic and statistical manual of mental
disorders; FOI, freedom of information; GP, general practitioner; GPwERs, GPs
with extended roles; IAPT, improving access to psychological therapies; ICD,
international classification of disease; NHS, national health service; NICE, national
institute for health and care excellence; UK, United Kingdom; UKAP, UK ADHD
partnership; UKAAN, UK adult ADHD Network; SIGN, Scottish intercollegiate
guidelines network.
and are likely to accumulate during the lifetime; for example,
research documents a trajectory of ADHD in childhood, leading
to academic and social problems which, in some cases, leads on
to depression (17).
Timely detection and treatment is likely to moderate
risks and improve outcomes (18, 19). ADHD is commonly
treated with psychostimulants, such as methylphenidate and
amphetamine. A recent systematic review and network meta-
analysis recommended methylphenidate for children and
adolescents and amphetamines for adults, taking into account
both efficacy and safety (20). Pharmaco-epidemiological studies
show that during periods on treatment, people with ADHD
have a lower risk of suicide (21), unintentional injury (11),
motor vehicle accidents and substance use disorders (19),
reduced hospital contact (22), better educational (23), and
occupational (24) outcomes, as well as reduced criminality (22).
Furthermore, evidence suggests delays in treatment lead to
high long-term personal and public costs, including reduced
economic productivity, and increased health, social care and
state benefit costs (25, 26). Effective psychological interventions
have been found to help increase employment and education
rates and reduce use of cash benefits and social services (27).
There has been a stepped change in clinical policy for treating
ADHD in the United Kingdom (UK) over the past three decades.
This has co-occurred with the mainstreaming of childhood
ADHD into generic mental health services, and the publication
of the first national clinical guidance on adult ADHD by the
National Institute for Clinical Excellence in 2008. As a result
of these changes and increased recognition of ADHD in the
population, there has been a significant increase in rates of first
diagnosis and prescribing of childhood ADHD (28, 29), and
many clinicians have seen their ADHD patient caseload and
waiting list increase significantly.
However, ADHD and its treatment remains controversial in
public, policy, and clinical spheres both in the UK (30–33) and in
other countries. The controversy centers around the perception
of ADHD as a medicalised social construct (34), represented
Frontiers in Psychiatry | www.frontiersin.org 2 March 2021 | Volume 12 | Article 649399
Young et al. Failure of ADHD Healthcare Provision
in some newspapers as a catchall for naughty behavior [see for
example (35)]. The increase in ADHD medication prescription
in the UK over the last two decades has been a cause of national
concern, provoking responses from health and educational
representatives (36, 37). Concerns have also been expressed
around the potential diversion and misuse of ADHD medication
as a “study drug” (38). This leads to short-sighted calls to curtail
prescriptions, but risks unfairly penalizing those who genuinely
need ADHDmedication.
However, contrary to concerns of over-medication, ADHD is
more likely to be under-identified, under-diagnosed and under-
treated in the UK (39, 40). Many of those who seek help face
patchy, unavailable and inaccessible services, and extremely long
waiting lists (41–43). Problems with access to services also affect
young people with ADHD in transition from child to adult
mental health services (44, 45). Patients report accumulated
psychosocial burden from delays in diagnosis and treatment (46).
Those who struggle to receive support are being signposted to, or
are seeking out, local or national service-user support groups for
help. These charitable organizations are inundated with support
requests that they are not always equipped or qualified to fulfill,
with certain regional exceptions. Those who are able to afford it
turn away from the National Health Service (NHS) and toward
private healthcare.
These problems have been exacerbated since the advent of
the COVID-19 pandemic. Efforts to delay the spread of the
virus have had an impact on demand and capacity to deliver
support for people with mental health needs. The pandemic is
associated with a range of social, financial, educational, health,
and personal concerns, which are all stressors associated with
mental health issues (47). Individuals with ADHD are likely to
be particularly vulnerable to the distress caused by the pandemic
and physical distancing measures, and may display increased
behavioral responses (48). They may also be at greater risk of
contracting COVID-19, a risk that appears to be exacerbated
in ADHD patients who are untreated (49). Although these
additional pressures on services have arisen more recently and
are likely to increase with the exacerbation of clinical needs in this
population, they have compounded already existing shortfalls.
Whilst acknowledging current challenges for mental health
provision and the increase in service provision for ADHD over
the past three decades, the existence of a significant unmet clinical
need for individuals with ADHD in the UK demands scrutiny.
With evidence of personal, clinical, social, and economic benefits
of investing in adequate treatment for ADHD, access to clinical
support must be improved not only in the context of the
pandemic, but also beyond. It is on the basis of these key
issues that professionals specializing in ADHD convened for a
consensus meeting to discuss the gap in ADHD provision in
the UK.
METHODS
The consensus group convened in London on the 11th
February 2019. The meeting was hosted by three leading
UK ADHD organizations; (1) the ADHD Foundation
(https://www.adhdfoundation.org.uk); (2) The UK ADHD
Partnership (UKAP, www.ukadhd.com) and; (3) the UK Adult
ADHD Network (UKAAN, www.ukaan.org). Meeting attendees
were academics, mental health professionals, educational and
occupational specialists, service-user support services and
charity workers specializing in ADHD. Healthcare practitioners
represented both those working within private practice, and
the National Health Service (NHS), the UK-wide universal
healthcare system providing free or low-cost healthcare to
UK residents.
The meeting commenced with presentations on (1) ADHD
provision in the UK from the viewpoint of the ADHD
Foundation, and (2) an overview of research on treatment and
short- and long-term outcomes of ADHD. This was followed by
a question and answer session, after which attendees separated
into three breakout groups, in which discussions were facilitated
by group leaders. Following the group work, all attendees re-
assembled. Group leaders then presented findings to all meeting
attendees for another round of discussion and debate, until
consensus was reached.
The National Institute for Health and Care Excellence (NICE)
guidelines provide clinical guidance for the diagnosis and
treatment of ADHD within the NHS across England and Wales
(50, 51), and adopted, as appropriate, in Northern Ireland
(52). The Scottish Intercollegiate Guidelines Network (SIGN),
provides the equivalent for Scotland (53). NICE guidelines were
used as a benchmark for service provision in these discussions,
since these provide official guidance for England and Wales and
there is good overlap between NICE and other recommendations
for the management of ADHD in SIGN.
Group discussions included the following three main topics,
each of which was explored for differences between children and
young people (age <18) and adults (age >18):
• How do we know children, young people and adults with
ADHD are not being diagnosed and why is this happening?
• Are the NHS services provided adequate?
• What is happening to those with ADHD who cannot access
NHS healthcare for their ADHD?
Presentations and debate amongst attendees were audio-
recorded and transcribed. During group breakout meetings,
a note-taker was allocated to each breakout group, and after
the consensus meeting notes were circulated to participants in
each breakout group for review. All materials (transcriptions,
electronic slide presentations, and breakout group notes) were
synthesized jointly by the lead author and writer.
Where relevant and available, consensus discussion points
are provided alongside references to the supporting research
literature, gray literature, policy or legislative documentation.
Where reports are anecdotal only and relate to the clinical
or professional experiences of consensus attendees, these are
described as such in the following report. A final draft
was circulated to all authors for approval before submission.
The consensus outcomes therefore represent the views and
recommendations of the authors in the consensus group as a
whole, reflecting the views of a range of professionals involved
in ADHD care and some key organizations working in this area.
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RESULTS AND CONSENSUS OUTCOME
Shortfalls in detection and service provision can be inferred from
discrepancies between community prevalence rates (defined
as the rate of ADHD in a large sample of people in the
general population) and administrative prevalence (defined as
the proportion of people with a recorded clinical diagnosis)
(39). Population prescription rates for ADHD medications are
often used as a proxy for clinical diagnosis in administrative
prevalence studies, but underestimate rates of diagnosis, since
they do not take account of patients who are managed without
ADHDmedications.
When considering community prevalence studies (using
similar methodological approaches) world estimates of the
prevalence of childhood ADHD have not changed in the past
three decades (54). By contrast, prescribing prevalence in the UK
has increased over this period of time (28). This shows that rates
of identification and access to treatment has improved over time,
although these continue to remain low across all ages. Similarly,
increases in rates of medication use for ADHD have been seen
across a range of different countries worldwide over this period
of time albeit with a broad discrepancy in treatment rates (40).
ADHD administrative prevalence (based on rates of diagnosis
and/or prescriptions) in children and adolescents in the UK
has been estimated to fall between 0.2 and 0.9% since the mid-
2000s (39). These rates remain below community prevalence
estimates in the UK estimated at around 2.2% in 1999 and 2005
(55, 56), with more recent estimates of 1.6% in 2017, based on
the more restrictive ICD-10 Hyperkinetic Disorder criteria (57).
Administrative prevalence of adult ADHD in the UK stands at
around 0.1% (40), far below even some of the lowest prevalence
rates documented in adults (9).
People with ADHD can face a long and difficult journey to
reach diagnosis and long-term management, described in some
cases as “an uphill struggle” (46). A number of hurdles to reaching
treatment were highlighted during the consensus meeting and
these are described in more detail in the sections below. Whilst
pathways to care for children and adults are distinct, barriers
to treatment are largely overlapping. After describing these
barriers, we provide recommendations for improving provision
and outcomes for people with ADHD.
Barriers to ADHD Diagnosis and Treatment
Provision
Detection of ADHD and Associated Problems
ADHD can only be diagnosed and treated as quickly as the
condition is identified in the community. However, there are
several reasons that it may go undetected. Expectations that
ADHD expresses only as hyperactive, restless, and disruptive
behavior may limit detection of the many more subtle
presentations. Although more subtle inattentive problems can
present across both sexes, they may disproportionately affect
detection of ADHD in girls and women (58). Furthermore,
lower rates of detection have been reported among minority
racial/ethnic groups in the United States (59) and more research
is required to examine for biases in operation for ADHD
treatment in relation to ethnic and racial status in the UK.
ADHD symptoms in those with higher intellectual
functioning and/or individuals applying a range of compensatory
strategies to reduce or mask their difficulties may also go
undetected. Even if detected, these individuals may not appear
to meet impairment thresholds for referral to secondary health
services and assessment.
Comorbidity is common and complicates identification and
treatment in ADHD. Common comorbidities in children include
autism spectrum disorders (ASD), mood, anxiety, oppositional,
and conduct disorders, as well as specific learning and language
disorders, epilepsy and Tourette’s syndrome (60, 61). In adults
with ADHD, comorbid symptoms and disorders are also
extremely common (62) and include ASD, mood, anxiety,
impulse control, and substance use disorders (63, 64). The
consensus group noted that with increasing age, people with
ADHD typically present with more co-occurring conditions,
which can lead to diagnostic overshadowing, making diagnosis
more complex andADHDmore likely to bemissed. Symptomatic
overlap with other disorders and a lack of awareness of ADHD in
clinical practice can lead to diagnostic mis-specification (65, 66).
As children age and become more independent, their
environmental support declines, whilst social, academic and
environmental demands increase (67). There is now increasing
evidence that in at least some cases, the full-blown disorder
emerges during the middle adolescent years, when more
demands are made on individuals and they fall further behind
their peers (68). Some young people with ADHD may develop
emotional dysregulation and comorbid disorders (for example,
mood disorders, eating disorders, and self-harm), triggering
inclusion into different treatment pathways.
People with ADHD may come in contact with a range of
mental health, social care or criminal justice professionals in
their lifetime. However, ADHD often remains unrecognized and
provisions are put in place for other conditions. This is evidenced
by the high rates of unrecognized ADHD in patient populations
treated for other psychiatric conditions [15.8–17.4% (69)], and
in prison populations [25.5% (70)]. Importantly, the consensus
group noted that adults with ADHD may show poor response
to the treatment of comorbid conditions if ADHD symptoms
are not appropriately managed. Symptoms such as emotional
instability, characteristic of many other mental health disorders,
often improve when ADHD is treated (71).
ADHD symptoms tend to decline with increasing age (7),
with greater decline seen for hyperactive-impulsive symptoms,
but less so for inattentive symptoms (72). Adults with ADHD
can therefore have a more subtle presentation characterized
by more internalized symptoms rather than overt externalized
behavior (1). The consensus group noted that with increasing
age people with ADHD may present with a variety of additional
difficulties (e.g., insomnia, anxiety, depression), and are less likely
to attribute problems to ADHD. In older adulthood there may
be confusion between the lifelong attentional problems of people
with undiagnosed ADHD and prodromal dementia (73). The
experience of adult mental health clinicians in the group was
that most patients presenting in adult ADHD clinics for the first
time had not previously received an assessment or diagnosis for
ADHD as children.
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Gatekeepers of ADHD Assessment and Diagnosis
In the UK healthcare system, a patient with ADHD passes
through multiple stages in the process of seeking help. The
knowledge and attitudes of the network of gatekeepers can
facilitate or hinder their access to support. One problem noted
repeatedly during the consensus meeting is that there is no
consistent referral route across all regions of the UK.
Parents/carers are often the first to seek out referral and
diagnosis for their children and their perception of the presenting
problem is a key contributor to primary care referrals to
community pediatric and/or Child and Adolescent Mental
Health Services (CAMHS) (33, 74). Similarly, the understanding
and attitude toward ADHD of help-seeking adults is likely to
affect their likelihood of self-referral.
Teachers are often the first (andmay be the only) professionals
approached by parents or carers (74). Teachers and educators
are also in regular contact with a large number of children and
young people and they are well-positioned to identify when
a child or young person is struggling. However, teachers are
more likely to raise concerns regarding ADHD when the child
presents with notable hyperactivity-impulsivity and associated
disruptive behavior (75). Furthermore, referral may be hindered
by overemphasizing the role of adverse home environments
and dietary factors as primary causes of symptoms (76) and/or
the perception that poor parenting is to blame (77). With the
diagnostic requirement that ADHD symptoms are pervasive and
present across two or more settings, school observations and
teacher input can support or undermine a legitimate referral for
assessment and diagnosis.
Primary care services are another main point of contact
for parents/carers and are usually the first port of call for
adults for onward referral for ADHD assessments. Unfortunately,
some primary and even some secondary care physicians express
uncertainty about the legitimacy of an ADHD diagnosis (78, 79).
They may have negative and unhelpful attitudes about ADHD
(46), and may perceive parental help-seeking as reflecting the
desire to “shift blame” or find a “quick fix” for behavioral or
disciplinary problems (80). As a result, some affected adults,
young people and their families may experience blame or
dismissal (30, 79).
Progressive revisions to diagnostic criteria and clinical
practice over the last 30 years have broadened the ADHD
phenotype. Some healthcare practitioners may not be aware
of these changes or may have limited “buy-in” (81), and still
be discounting a variety of ADHD presentations, such as
adult ADHD, ADHD comorbid with ASD, or inattentive only
presentations. These presentations may bemet with an extra dose
of distrust, particularly for adult ADHD for which the consensus
group noted stigma remains particularly high.
ADHD Healthcare Organization in the UK
The consensus group noted that there are local and regional
idiosyncrasies in referral pathways and treatment arrangements
for both child and adult ADHD services, which can make it
challenging to navigate access to care.
Insight into health service provision in the UK can be obtained
from public authorities through legislative rights under the
Freedom of Information (FOI) act of 2000 (82), which allows
access to information on the daily workings of public services.
However, the information provided may not be complete and
a non-response may reflect a reluctance to report on gaps in
services or other constraints, such as lack of time or staff to
respond (83). Statistics such as waiting times can be misleading
due to, for example, closure of referrals and waiting lists
once services reach capacity (84), or due to internal triaging
where there is an initial waiting list for a generic assessment
followed by yet another waiting list for ADHD assessment in
patients with suspected ADHD. This practice of undisclosed data
manipulation, can make the FOI data provided impossible to
interpret straightforwardly and more difficult still to compare
across services or regions.
ADHD Service Pathways in Children
At primary school age, ADHD is diagnosed and treated by
Developmental Pediatricians in some regions or CAMHS in
others; at secondary school-age it is usually managed through
generic mental health services for children and young people
[Community Child Health (CCH) or CAMHS]; in older
teenagers and in adulthood the service is provided by specialist
ADHD services or Adult Mental Health Services (AMHS) with
expertise in ADHD.
After diagnosis and medication titration (where indicated) in
secondary care, clinical care is often, but not always, transferred
back to primary health through shared care protocols. Where
this is the case, GPs assume responsibility for prescribing and
providing routine physical check-ups. NICE then recommends
that annual reviews of ADHD medication be conducted by
healthcare professionals with training and expertise in managing
ADHD (50).
A report from the Education Policy Institute using data from
FOI requests fromCAMHS Services revealed a “postcode lottery”
for access to general mental healthcare. Median waiting times
ranged from 1 day to 6 months and there was wide variation
in the rates of referral rejection, with specialist mental health
services rejecting referrals from as many as one in four children
(24.2%) in 2017/18 (41). The most common justification for
rejection was that the referred mental health conditions were not
serious enough tomeet the eligibility criteria for treatment, which
included young people who had self-harmed or experienced
abuse. Whilst these statistics do not reflect wait times and
rejection rates for ADHD in particular, they highlight problems
with mental health provision across CAMHS. Long waiting times
were also reported in a 2016 survey by the Royal College of
Pediatrics and Child Health. They reported that the average time
from referral to diagnosis for ADHD exceeded 6 months for
Community Child Health teams (42, 43).
The consensus group discussed the erratic way in which
exclusionary criteria from service provision is applied. From the
experience of the consensus group, some services only accept
children and young people with ADHD when a patient presents
with comorbidity. Others only accept those presenting with acute
comorbidity (such as self-harming behaviors or eating disorders).
Charity representatives spoke of instances when access to services
had been declined to children as young as 14 years due to
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waiting lists that were so long the child would exceed the
age cut-off for the service before they were seen. Anecdotal
accounts were provided of young people with ADHD and severe
comorbidities (self-harm, eating disorders, attempted suicide)
being refused treatment for these comorbidities, on the basis that
they were attributed to impulsivity (rather than a reflection of
mental distress and an intention to self-harm) and their existing
diagnosis of ADHD. The effect of these policies is that vulnerable
young people and families seeking support are turned away,
refused access to healthcare, and do not receive any support at all.
ADHD Service Pathways in Adults
Evidence suggests a similar “postcode lottery” for access to
adult ADHD services, albeit with even longer waiting lists. A
national survey found patchy provision of services for adults
with ADHD (85), and in some localities services simply did not
exist at all. In regions without adult ADHD specialist services,
individuals should, by right under the NHS Constitution, be
able to access these services elsewhere (86), however service
commissioners may delay or refuse to fund out-of-area ADHD
treatment (87). As a result, some people with ADHD are left
in limbo, unable to access clinical care or social support, and
unable to benefit from their legal rights and support systems
associated with their disability. Help-seeking pathways for those
suspecting a diagnosis of adult ADHD are shown in Figure 1.
These pathways do not reflect how the healthcare systems should
be structured, but rather provide an overview of the complex
pathways that patients may take when seeking support for
ADHD. Furthermore, this simplified schema shows key points
at which patients may seek out help external to the NHS,
either from voluntary or charitable organizations or from private
health services.
Clinical Commissioning Groups (CCGs) are regional bodies
of the NHS, which allocate, plan and provide services for
populations within specific service regions. A review of
ADHD provision in CCGs in England was undertaken in
2018 with Freedom of Information (FOI) requests by Takeda
pharmaceuticals and the report was supported and endorsed
by the ADHD Foundation charity (88). This report revealed
a lack of oversight for demographic need for ADHD services
by CCGs: only around one-third of CCG respondents provided
information about waiting times or budget spent on ADHD
services; less than one-third gave an estimate of the number of
ADHD patients for whom they commissioned services. Where
information was provided regarding the average waiting time
from referral to assessment, this spanned from 4 weeks to 3.8
years (average 14 months). In July 2020, BBC News reported FOI
data on adult ADHD waiting lists from 33 NHS trusts. A total of
20,859 adults were on waiting lists for ADHD services; 11 trusts
had maximal waiting times of at least 2 years; and some reported
waiting times of over five (89).
Internal reports from NHS governing bodies in certain parts
of the country show the tensions that arise between the desire to
reduce long patient waiting times, the likely additional costs from
increased service investment and resultant increased prescription
rates (90, 91). These conflicts may effectively paralyze progress
in terms of increasing service delivery for affected patients.
Financial constraints within individual services reveal themyopic
nature of treatment and commissioning arrangements. This
is particularly true for people with ADHD where treatment
shortfalls are associated with significantly increased societal and
personal costs, and which are shouldered elsewhere in the health,
social care and judicial systems.
Barriers to Treatment
NICE guidelines emphasize the importance of recognition of
ADHD, diagnosis and treatment, continuity of care, and ensuring
that people with ADHD have a comprehensive, holistic shared
treatment plan that addresses psychological, behavioral, and
occupational or educational needs (50). However, access to
treatment is not always straightforward, even for those who are
already diagnosed. The consensus group identified four key areas
of concern, outlined below.
Lost in Transition
Transition in healthcare refers to the process of transferring the
clinical care of a patient from child to adult services, which
occurs by the age of 18 years in most cases. There are multiple
possible transition pathways in the NHS which vary regionally,
and include referral to Adult Mental Health Services (AMHS), to
specialist ADHD services or to GPs in primary care.
NICE guidelines recommend that young people with ADHD
receiving treatment from CAMHS or pediatric services should
be assessed at transition age, and then if needed transferred to
adult services, where they should be re-assessed (50). Transfer
of care should occur alongside a handover of full information,
formal meetings between child and adult services, with planning
of transition including the young person (50). Specific guidance
is available regarding the implementation of NICE guidelines
to achieve successful transition between services for young
people with ADHD (92). However, in practice NICE guidelines
on transition are often not implemented due to resource and
time constraints and the multiple structural and organizational
barriers in which service providers operate (78, 93, 94).
Transition takes place at a critical juncture in young people’s
lives and there are understandable concerns about the effects
of sudden treatment cessation on their educational and/or
occupational outcomes (95). One study of prescribing rates
showed that rates of primary care prescribing of ADHD
medication for young people in the UK declined more steeply
than expected given the rate of symptom reduction—suggesting
that some may experience cessation of medication due to a
change of services rather than due to symptoms declining (96).
The consensus group noted that treatment cessation may
arise from adolescents electively disengaging with clinical
services. Others may be discharged or lost to follow-up during
the transition stage for a range of reasons: a lack of adult
services to which they can be referred, not meeting criteria
for inclusion in adult service criteria (severity or impairment);
a lack of knowledge or resources for treating ADHD within
available services; and failure to attend the first post transition
appointment (78, 93, 97–99). The CATCh-uS study prospectively
examined transition into adult services in young people with
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FIGURE 1 | Successful and unsuccessful pathways to Adult ADHD treatment initiation and maintenance. This simplified schema shows the interaction between NHS
bodies and services, voluntary and charitable organizations, and private health services. Shared care arrangements are shown on a dark green background. Note that
in the experience of the consensus group, shared care between NHS and private practices (red dashed line) are infrequently supported. NHS, national health services;
ADHD, attention-deficit/hyperactivity disorder.
ADHD in the UK, and found that only 1 in 5 eligible young
people transitioned successfully (99).
When transition to adult ADHD services is unsuccessful,
child mental health services may be left with the responsibility
of continuing care, further decreasing their capacity to respond
to new referrals (100). In some regions, ADHD services
for children are supported entirely by CAMHS without
involvement community pediatric services, and with limited
availability of shared care prescribing with primary care
services. On transition, primary care providers are suddenly
expected to take over the unfamiliar role of long-term
routine monitoring of ADHD medication in these same
patients, without specialist oversight as recommended in NICE
guidelines, and may refuse. As a result, young people with
ADHD may suddenly and unexpectedly lose access to their
usual treatments.
In cases where treatment is stopped during adolescent years,
the consensus group noted that it can be difficult for young
people to restart treatment again.
Lost in Communication
NICE guidelines state that ADHD diagnosis and medication
initiation and titration should be conducted by a specialist in
ADHD (50). Once patients have been stabilized on medication,
treatment can be managed and monitored jointly with primary
care, under a shared care protocol. Specialist review is
recommended on an annual basis, but routine check-ups and
prescribing can be completed in primary health. This frees up
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some capacity within secondary health services, allowing them
to take on new referrals and manage more complicated cases.
However, often shared care arrangements fall apart, seriously
disadvantaging patients caught in the middle. This can be
due to lack of agreement or inadequate communication, or
where primary care practitioners are concerned about assuming
responsibility for an unfamiliar treatment (101). Insufficient
support from secondary healthcare services may undermine
continuity of care for affected patients. For example, a Royal
College of Pediatrics and Child Health report published in 2017
showed that only 11.4% of Community Child Health (CCH)
services could always see ADHD patients when follow-up was
due, and 60% could do so no more than half the time, raising
issues of medication safety (43).
Primary care practitioners may feel that ADHD symptom
monitoring is not in their remit, and some believe that
prescribing for ADHD should not be carried out by primary care
(80, 102). Reasons for not prescribing include concerns regarding
the diagnosis, the unavailability of non-pharmacological
treatment, and potential inadequacy of physical monitoring
in secondary care (102). Primary care practitioners also voice
concerns around the nature of medication in terms of stimulants
being “controlled drugs,” and risk of potential misuse and
diversion (103), they may lack confidence in managing ADHD
treatment, due to knowledge limitations, insufficient training
and/or poor communication from specialist services (104). In
a survey of 150 General Practitioners (GPs), 64% stated that
they would be likely to change their views on prescribing with
clearer advice from specialists, and 67% said they would be
influenced if there was a clear protocol for monitoring a child on
medication (104).
Problems with shared care may lead to patients navigating a
complex system of referral for assessment, obtaining a diagnosis
and initiating treatments under a specialist (sometimes after
many years of seeking treatment), and then having treatment
denied due to the failure of shared care.
As well as posing a risk to the safety, health and well-being
of patients, breakdown of treatment provision due to failure of
shared care represents a waste of health resources that are already
in short supply.
Non-pharmacological Treatment
Pharmacotherapy for ADHD as a standalone treatment is
unlikely to address the needs and impairments associated
with ADHD fully (105). It does not provide direct support for
common problems associated with ADHD, such as psychosocial,
emotional and peer problems, behavioral difficulties and
other comorbid conditions. A range of non-pharmacological
approaches may be helpful working in cooperation with
patients themselves, schools, parents/carers, educational and/or
workplace settings. These include (provided in individual
and/or group format) cognitive behavioral therapy (CBT),
psychoeducation, parent mediated/training interventions,
school/classroom interventions and occupational therapy (105).
Although some commissioners and healthcare practitioners
recognize the value of multimodal treatments consisting of
non-pharmacological interventions alongside medication (106),
psychological therapies for ADHD are often not implemented
because they are considered to be expensive, because they are in
short supply or simply not available.
For children and young people, treatment options are often
rigid in nature, and not tailored to patients’ needs. Parent/carer
training interventions are the main (and sometimes only) option.
However, since many of these interventions have been developed
for children with externalizing and conduct problems (107), they
are not always appropriate for supporting the needs teenagers
and young people with ADHD (105) who require more direct
support, and those with inattentive symptoms or subtler or more
nuanced presentations.
Psychological interventions are rarely available for adults with
ADHD, and medication is often the only treatment offered. A
recent mapping study found that only 12 out of 44 dedicated
adult ADHD services (27%) provided the full range of treatments
recommended by NICE including psychological therapy (85).
The consensus group noted that adults with ADHD may be
more likely to be offered non-pharmacological treatments for
coexisting conditions, although these frequently do not take
ADHD and its associated difficulties into account.
Plugging the Gaps
When faced with long waiting times, patchy and unavailable
services, blame or dismissal, affected individuals and their
families may turn to other services and sectors to gain the support
they need (see Figure 1).
Charitable and other support organizations provide a range
of invaluable non-clinical services for people with ADHD
at low cost or free of charge. These services include:
information dissemination, signposting, peer and social support,
friendship and preventing loneliness, advice clinics, coaching
and psychoeducation, group and family therapy, and parenting
programmes. Their websites provide access to freely available
curated resources and/or help to direct people to relevant tools
and support information. Services are not regulated however, and
availability, resources and expertise vary considerably between
areas and organizations, giving uneven coverage across the UK.
Support group representatives at the consensus meeting
reported that patients are seeking out (and in some cases being
actively directed to) local or national support groups for help.
Informal referrals from theNHS led them to feel like a “secondary
NHS” service, inundated with support requests that they felt ill-
equipped and unqualified to fulfill. Their staff do not always have
the training or expertise to support the vulnerable, distressed and
at times suicidal individuals with ADHD, for whom help from
clinical health services is delayed or refused.
Some affected individuals and families are driven to seek
out costly private clinical services (26). For many, this is not
an option for financial reasons. This leads to a 2-tier health
service, unfairly penalizing lower income families and patients
and leading to a gap in provision. Clinical assessment and
treatment in the private sector can be costly. This is not a
“one off” assessment service as it often requires further titration
appointments, (repeat) prescriptions and non-pharmacological
services. These can become unaffordable in the longer-term even
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for middle income patients and families, particularly for those
with more complex clinical presentation and treatment needs.
Some patients and families seek only ADHD assessment in
private clinics in order to circumvent gaps or blockages in
access to care, in the hope of reintegrating into public healthcare
provision by returning to the NHS (e.g., Figure 1). However,
there is an absence of transparency regarding the expertise in
ADHD and the quality of care provided in the private sector.
NHS providers may have reasonable concerns regarding the
validity of certain privately formulated diagnoses, which may
leave NHS providers with no choice but to refuse treatment,
leaving affected patients unable to access the support that
they need.
Concerns around the quality of assessments and clinical
reports for ADHD were an area of serious debate during
the consensus meeting. Consensus participants (including
private and NHS clinicians, stakeholders and support group
representatives) reported problems with private healthcare
providers capitalizing on the desperation of patients who feel
let down by the public healthcare system. The upshot is that
some patients seeking out private services for ADHD do not
receive appropriate assessments or treatment that follow clinical
guidelines. In some cases, private ADHD assessment reports
do not contain enough information to show that diagnostic
thresholds had been met or do not clarify if the required
in-depth examination was carried out, and therefore patients’
diagnoses cannot be accepted at other clinics until they are
given a more comprehensive assessment. Consensus participants
reported cases of ADHD diagnostic reports written by assessors
without appropriate clinical qualifications (i.e., those without
core clinical training in assessing differential diagnosis and/or
comorbid conditions) and/or who are not registered with a UK
health regulator (e.g., Health and Care Professionals Council,
General Medical Council).
Recommendations
The consensus group identified essential changes that can and
should be made to improve outcomes for people affected by
ADHD. Solutions include training and education across all
sectors; revising models of care to improve access to treatment;
a focus on joining up services; methods to improve consistency
in diagnosis and treatment across service sectors; broadening
access to non-pharmacological treatments; and funding and
commissioning for ADHD.
Training and Education Across All Sectors
Access to evidence-based training will address the issue of
awareness and attitudes of key professional groups in the public
sector and improve recognition and support for individuals with
ADHD. Ideally, this should reach all healthcare professionals
(including primary care providers), educational professionals,
youth center employees, social workers, the police, and those
working with prisoners or youth offenders.
Training should incorporate heterogeneity of ADHD
(described in section Detection of ADHD and associated
problems), to improve detection of more subtle presentations.
Key professionals need to be informed of the biological and
medical evidence to help shift blame away from parenting and
the home environment. An emphasis on longer-term outcomes
of effective treatment may help to reduce the perception that
those seeking ADHD treatment are looking for a “quick fix.”
ADHD awareness for educational professionals should be
developed for schools and higher education institutions to
improve referrals from the education sector. Where possible,
educational psychologists or mental health professionals working
in schools should be engaged to assist with development and
implementation of training.
Empowering Primary and Secondary Care in the
Management of Adult ADHD
The consensus group agreed that competency in ADHD should
ideally occur alongside competency for other common mental
health conditions: for clinicians already diagnosing and treating
anxiety and depression, concurrent assessment and treatment
for ADHD (where appropriate) would improve the targeting
of treatments, lead to better outcomes, and reduce patient
and clinical burden. There should be adequate knowledge
and specialism of ADHD within all secondary mental health
practices, as there is for other common mental health conditions.
In accordance with NICE guidelines (108), a broad range
of health professionals (psychiatrist, pediatrician, clinical
psychologist or other appropriately qualified healthcare
professional) can with adequate training, acquire the necessary
knowledge of ADHD to support its assessment and/or treatment.
Primary care physicians, including general practitioners
(GPs), already have an important role in raising suspicion for
a possible diagnosis, making a timely referral and supporting
monitoring and continuation of treatment under shared care
protocols. Providing, and encouraging primary care practitioners
to participate in, training about ADHD was considered to be
an important first step, and encouraging some GPs and practice
nurses in taking on additional training to qualify as GPs with
extended roles (GPwERs) or specialist nurses with extended
roles, respectively, was considered practical and sustainable for
improving expertise in in primary care in the first instance.
Overall, the group was in agreement that a level of competence
in the recognition and understanding of ADHD was key, as well
as clear pathways to more specialist support.
In the longer term, integration of ADHD into broader mental
healthcare provision in primary care would be required to further
streamline provision and remove bottlenecks. However, this
arrangement has implications for GP workloads, and would
require additional workforce management, staff and resource
provision. The new Primary Care Network model, described in
the NHS Long Term Plan in 2019 (109), aims to pool expertise
at a primary care level within local areas. Primary care at scale,
with practices joining together to pool expertise and resources
in larger primary care networks with 30,000–50,000 patients,
may help to address implications for workforce management and
resource provision.
Joining Up Services
We have shown a disjoint between primary and secondary
care, and child and adult services, which leaves patients with
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ADHD unable to access or maintain treatment. Improved
communication is key to joining up services. When primary
care services are asked to take over prescribing from secondary
health providers there needs to be support and guidance available
for treating clinicians, with specialist advice readily available.
Examples of integrated care between GPs and specialist services
for chronic illnesses such as heart failure have been reported
previously, resulting in improved coordination, GPs feeling more
confident in supporting their patients, specialists receiving more
detailed feedback from primary care, and patients themselves
benefiting from more streamlined and holistic care (110).
Longer-term, staff with specialist or extended roles within
primary care networks, as described above, could help to close
the gap in accessing diagnostic and intervention services, and
liaise with and between secondary care services and psychological
services as needed to provide the correct intensity of support and
the required continuity of care.
Improving Consistency in Diagnosis and Treatment
Consensus meeting discussions highlighted the importance of
regulating private ADHD practices to improve consistency of
ADHD diagnosis, assessment reporting and treatment, and to
ensure adequate qualification of providers.
The consensus group also noted varying quality in ADHD
assessments within the NHS, albeit to a lesser extent. These
problems led to discussions within the consensus group on
the minimum standards for an ADHD diagnostic assessment.
These were agreed on and are summarized in Table 1.
Adhering to minimum diagnostic standards may help to
support an ADHD diagnosis obtained in private healthcare for
those wishing to return to NHS treatment. These standards
can also help patients to understand which investigations
to expect from an ADHD assessment, and what to expect
from their diagnostic report, and provide confidence in
their diagnosis. Patients/clinicians can also examine reports
from Care Quality Commission in the UK, which monitors,
inspects and regulates healthcare services, including private
and NHS healthcare services. Inspection reports can provide
an initial overview of the quality of individual private
services, and are publicly available on the Care Quality
Commission website.
Improving Access to Non-pharmacological Treatment
The consensus group agreed that access to non-pharmacological
treatment should be improved for patients with ADHD.
Treatment options should include a broader range of non-
pharmacological interventions, tailored to developmental age
and need.
In accord with NICE guidelines, the group emphasized
the importance of access to high-quality age-appropriate
psychoeducation for everyone with a new diagnosis of ADHD
and their families. Evidence suggests that psychoeducation
may help to improve clinical and subjective outcomes as well
as medication adherence (111). Some initial psychoeducation
should be provided at the point of diagnosis of ADHD by the
diagnosing clinician. Further enhanced psychoeducation should
TABLE 1 | Minimum standards for ADHD assessment and report.
ADHD diagnostic assessments should be of an adequate length to cover all
aspects described below and provide detail and generate examples of
behaviors or problems. The clinician completing the assessment should be
highly familiar with and/or specialize in ADHD but will require specialism
beyond ADHD to identify comorbidities and complexities. Patients should
not usually expect to receive their diagnostic report on the same day as their
assessment.
Assessments should include:
• Structured clinical interview according to up-to-date DSM or ICD
publications, including:
◦ Developmental history
◦ Medical and physical health history




◦ Exploration of potential comorbid problems/differential diagnosis
◦ Risk assessment
• Collateral information to inform assessment, if available, can be used to
augment clinical decision making and should not be used as stand-alone
diagnostic tools. e.g., rating scales, information from informants (including
schools), school and/or other reports, and objective tests of attention,
impulsivity and/or motor activity.
• Mental state examination
• Physical assessment: physical observation, pulse, blood pressure, height
and weight, cardiovascular assessment, and referral for other types of
physical examination if indicated.
Diagnostic reports should include:
• Description of diagnostic assessment completed (e.g., measures,
corroborating information)
• Clear diagnosis and formulation.
• Outline of symptoms and impairments
• Coexisting diagnosis and associated problems
Risks
• An outline of strengths in the assessment report
• Individualized recommendations, including treatment plans
(pharmacological, non-pharmacological, multi-agency liaison).
• Contact details for local service-user support services
be tiered based on severity and complexity of patient needs and
consider comorbidity.
In children and young people, age- and presentation-
appropriate psychological interventions (beyond parent/carer
training for behavioral problems) should bemade available in line
with NICE guidelines.
Psychological interventions should also be increased for
adults with ADHD. Aside from symptom management,
these should address the specific difficulties experienced
by young people and adults with ADHD (e.g., emotional
lability and dysregulation, educational and employment
problems, interpersonal difficulties, antisocial behavior and the
development of prosocial competence, substance misuse, self-
harm, dysfunctional coping strategies, and comorbid conditions
such as anxiety and depression). Services such as IAPT
(Improving Access to Psychological Therapies), which provide
psychological therapies for adults with anxiety and depression in
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the community, could be useful resources for adults with ADHD
if opened up or adapted for this patient group.
Funding and Commissioning for ADHD
ADHD is a common mental health condition. However, this
contrasts to the clinical provision model, where diagnosis,
treatment initiation and monitoring is constrained to scarce
and limited capacity specialist health resources. The experience
of the consensus group was that services struggle with the
capacity vs. demand conundrum, and that many service
providers are passionate about providing the best support that
circumstances and local commissioning parameters allow.
The rights of people with ADHD are supported by the UK
Equality Act (112). Clear guidance on clinical practice to support
healthcare in ADHD is spelled out in national clinical guidelines.
NICE guidance is linked to each CCG’s responsibility and legal
duty to regard NICE quality standards and recommendations,
secure high quality services and ensure continual improvement
in the quality of local NHS services (in addition to their legal
duty to reduce health inequalities) as set out in the NHS
Constitution (113) and The National Health Service Act (2006)
(114) as amended by The Health and Social Care Act (2012)
(115). Furthermore, it appears that courts are increasingly willing
to acknowledge that national guidance may be relevant (in
conjunction with clinical judgement) in setting standards of care
because they are evidence based and reflect reasonable medical
practice (116). This means CCGs and clinicians are potentially at
risk of being challenged if they ignore NICE Guidance and they
should only do that if they have something better to offer.
The rights of people with ADHD in the UK are also protected
under the Human Rights Act 1998 (article 14: right to non-
discrimination), and further under the UK Equality Act 2010,
which protects people with a disability (including ADHD).
People with ADHD also have rights under the Public Sector
Equality Duty in England, Scotland and Wales, which places an
obligation on public authorities to positively promote equality,
not merely to avoid discrimination.
However, the existence of these clinical guidelines and the
legislation to underpin them has not hindered people in key
positions for referral, diagnosis and service commissioning from
denying access to treatment and support to affected individuals.
It is also clear that some CCGs are not commissioning or staffing
adequate services for ADHD, and are therefore disregarding
clinical evidence, national clinical guidelines, and their legal duty
to prevent health inequality and discrimination. This problem is
most clearly shown for adults with ADHD, for whom services
are simply not available in certain regions, or to whom access
to NHS services in other areas are not made available. In order
for UK-wide clinical guidelines to be meaningful and effectively
implemented, funding and service development needs to increase
to meet the burden of illness.
The fragmentation of funding across public services in the UK
means that it can be difficult to convince health commissioners
to see ADHD treatment as a broader investment in health,
education, social services, the criminal justice system and the
economy in general. Longer-term benefits are also a hard sell
for commissioners who work toward a fixed annual budget,
with competing needs from different mental health groups and
services that are already over-stretched. Commissioners must
be informed on the robust evidence for the long-term negative
outcomes associated with ADHD (especially if untreated) and
their economic implications (25).
Long-term planning of funding (now implemented in some
regions in the UK) is needed to circumvent problems arising
from “short-termism” of care. Joined-up commissioning between
state-funded health, social services, and judicial servicesmay help
to reduce fragmentation of care and cost burdens.
DISCUSSION
ADHD is the most highly prevalent childhood condition and is
also common in adults. There is robust evidence for negative
health and social outcomes. Yet many young people and adults
are not able to obtain a timely diagnosis and treatment. Clinical
guidelines are not being implemented and there is huge variation
in the commissioning of ADHD services across the UK.
The current paper highlights discrepancies between
clinical guidelines and provision in key areas (e.g., basic
service availability and access, transition from child to adult
services, shared care, non-pharmacological treatment). These
discrepancies occur at multiple points in the healthcare system
and often have complex socio-cultural, health-structural,
funding, commissioning, and resource-based underpinnings.
However, despite the underlying complexity of the system, it
must be said that unmet needs correspond to denied rights,
particularly in a universal health service.
The greatest barrier to services for people with ADHD is lack
of awareness and stigma associated with the ADHD diagnosis.
From the patient perspective, stigma and lack of recognition of
the condition create a barrier to accessing treatment and support
systems. From a commissioning and service delivery standpoint,
lack of understanding and stigma constrict allocation of funding
and resources. As the current report shows, prejudice and lack
of understanding influence all levels of the healthcare system,
resulting in a de-prioritization of ADHD and its treatment. This
also has an effect on the physical and mental health and well-
being of patients and their families who struggle to access the
support they are entitled to and face ill-placed blame. Delays and
inability to obtain treatment lead to increasing morbidity and
functional impairment.
Most importantly, we need to end acceptance of stigma against
people with ADHD as a valid viewpoint in the healthcare sector.
The growing strength of vocal and active support groups and
charities across the country have provided an emergent patient
voice and public visibility of the condition has improved. Widely
publicized reports produced by, or in association with, these
charities and support groups have also helped to raise the profile
of ADHD and associated problems (26, 88), and positively
influence the nature of reporting around the condition.
We should now be looking toward improving access to
treatment for children and adults with ADHD. A brief overview
and summary of the consensus recommendations is presented in
Table 2.
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TABLE 2 | Overview and recommendations.
• There is an urgent need to tackle the underlying structural,
social, and economic restrictions that de-prioritize mental health
and ADHD in healthcare.
• Training for ADHD should be provided across disciplines and
sectors to reduce stigma and misinformation and
improve detection.
• Longer-term planning and budgeting are required to provide a
“whole person” approach and reduce short-termism and
fragmentation of care.
• Devolving of health and social care within one budget can help
to reduce service fragmentation.
• Additional efforts and investment are needed to join up
components of clinical service delivery from child to adult
services, and between secondary and primary health.
• Current healthcare provision for ADHD in the UK is overly
complex and regionally variable. We need to look toward new
models of integrated care to provide more streamlined and
effective neurodevelopmental services.
• ADHD should be viewed as part of common adult mental health,
rather than a specialist diagnosis. Due to its high prevalence,
and high comorbidity with other mental health conditions, adult
ADHD should be mainstreamed into secondary care.
• Reinforcement for ADHD services from primary care is likely to
be needed to support treatment in the longer-term.
Information provision and training for key professional
groups, including healthcare and educational professionals,
could lead to more timely and appropriate referrals, assessment
and treatment. Reducing stigma and increasing understanding
of ADHD may help to improve understanding and increase
referrals to clinical services.
Whilst the rights of individuals with ADHD are strong
under current UK legislation and existing clinical guidelines,
accountability of services and service commissioners to these
rights and guidelines is uneven. Greater regulatory and legislative
support for ADHD could go a long way toward reducing stigma
and opening up pathways to healthcare. In 2018 an All-Party
Parliamentary Group for ADHD was launched at the Houses of
Parliament. Whilst this provided a positive platform there have
yet to be any tangible outcomes. In 2017 the charity ADHD
Action called upon the Government to pass an ADHD Act that
would meet the needs of adults and children with ADHD (117).
Their petition received 11,806 signatures but was not supported
by the government. A second petition was recently launched
(118), currently reaching over 10,000 signatures.
However, legislation and regulation alone will not ease the
problems of overly complex, overstretched and fragmented
services. Mainstreaming ADHD provision into general adult
mental health services, and introducing new expertise within
primary care across child and adult ADHD healthcare provision
can help to improve detection, take the pressure away from
over-stretched specialist services, and enhance communication
throughout the healthcare system. Enhancing information flow
between primary and secondary care services, and child and adult
services can help to reduce the likelihood that diagnosed patients
find themselves falling between the edges of service boundaries,
unable to access the treatment they need.
Whilst implementing the above recommendations will entail
additional costs to the UK healthcare system in the short term,
economic analyses indicate that leaving ADHD untreated or
undetected is not a cost-saving exercise. Evidence suggests delays
in effective treatment lead to high long-term personal and public
costs, including reduced economic productivity, and increased
health, social care and state benefit costs (25, 26). Further
investment in mental health in general, and ADHD in particular,
is required to support the services which are groaning under the
weight of demand.
As we move toward resuming mental health services in the
post COVID-19 era, we must look to how we can improve access
and treatment in the future. Guidelines now exist on ADHD
management and treatment initiation during the COVID-19
pandemic (48, 119). Much can be achieved at distance using
digital communications, which can help clinics to resume patient
contact, assessment and treatment monitoring. However, these
are merely short-term solutions that alleviate problems at the
tip of the iceberg. Much larger changes, in terms of workforce
education, service deliverymodeling and financial investment are
needed to resolve the broader issues described.
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